kreon 10 000
viatris healthcare limited, Írsko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida
kreon 25 000
viatris healthcare limited, Írsko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida
kreon 40 000
mylan ire healthcare limited, Írsko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida
alunbrig
takeda pharma a/s - brigatinib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
glybera
uniqure biopharma b.v. - alipogene tiparvovec - hyperlipoproteinémia typu i - Činidlá modifikujúce lipidy - glybera je indikovaný pre dospelých pacientov diagnostikovaná familiárna lipoproteínu lipázy (lpld) a trpiacich závažnou alebo viacerých pankreatitída útoky napriek tuku diétne obmedzenia. diagnóza lpld musí byť potvrdená genetickým testovaním. indikácia je obmedzená na pacientov s detegovateľnými hladinami lpl proteínu.
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastické činidlá - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
scemblix
novartis europharm limited - asciminib hydrochloride - leukémia, myelogénna, chronická, bcr-abl pozitívna - antineoplastické činidlá - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.
panzytrat 25 000
abbvie s.r.o., slovensko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida
panzytrat 10 000
allergan pharmaceuticals international ltd., Írsko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida
panzynorm 10 000
krka, d.d., novo mesto, slovinsko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida